Hi Lynn,
I would like to participate. Please count me in.
Thanks,
Seema
------------------------------
Seema Kumar Ph.D.
Director, Head of Clinical Bioanalytical Sciences
EMD Serono, a business of Merck KGaA, Germany
Billerica MA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------
Original Message:
Sent: 02-22-2023 09:30
From: Weifeng Xu
Subject: Strategies for optimizing Neutralizing Antibody Assays
Thanks Lynn! Here is the linker for the paper that we are going to discuss: https://rdcu.be/c4brb
------------------------------
Weifeng Xu
Director
Merck
West Point PA
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
Original Message:
Sent: 02-16-2023 19:55
From: Lynn Kamen
Subject: Strategies for optimizing Neutralizing Antibody Assays
Next month, in the Neutralizing Antibody Assay Subteam, we will be discussing the just published work in the AAPS Journal on using a new method to overcome drug interference in Neutralizing Antibody assays (named Precipitation, Acid Dissociation and Biotin-drug as Assay Drug, PABAD). If you would like to participate in this discussion and join our group, please contact myself or my co-lead Weifeng Xu.
------------------------------
Lynn Kamen
Scientific Officer, Executive Director
BioAgilytix Labs
Durham NC
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------